| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8452902 | Hematology/Oncology and Stem Cell Therapy | 2017 | 4 Pages |
Abstract
Obinutuzumab has an established safety profile in patients with CLL, but our case is the first reported case of a paraneoplastic, immune complex-mediated MPGN in CLL being treated with obinutuzumab. Obinutuzumab should be explored as a potential option in patients with CLL and MPGN.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Punit Jain, Rashmi Kanagal-Shamanna, William Wierda, Alessandra Ferrajoli, Michael Keating, Nitin Jain,